Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
| Study title | Condition | Phase | Location |
|---|---|---|---|
A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis |
Relapsing Multiple Sclerosis | Germany | |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) | Phase3 | United States Israel Japan Italy Thailand Spain France Romania Argentina Australia China Hungary Germany Malaysia United Kingdom India Singapore Taiwan View All |
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan |
Prostate Cancer | Phase2 | Japan |
Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer | Phase1 | United States Spain Japan Germany Switzerland Korea, Republic of View All |
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases |
Myeloid Diseases | Phase1 | United States Italy Germany France Hong Kong Spain Singapore View All |
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL |
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase1, Phase2 | United States Spain Italy Japan Germany France Australia Austria View All |
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors |
Mesothelioma | Phase1 | United States Spain Japan Germany United Kingdom Australia Italy Canada Netherlands France Switzerland View All |
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf |
Relapsing Multiple Sclerosis | United Arab Emirates Oman |
|
A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China |
Retinopathy of Prematurity | China | |
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
Lupus Nephritis | Phase2 | Turkey Israel United States China Germany Portugal Hungary Malaysia Spain France Mexico India Hong Kong Puerto Rico Brazil Singapore View All |